# Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure

> **NCT00633477** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 18 (actual)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** Resatorvid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00633477
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Business Decision; No Safety Or Efficacy Concerns.
- **Last updated:** 2013-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633477, "Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00633477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*